Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Mind medicine | Mind Blowing Facts

Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026

As mental health treatment evolves, MindMed’s advancing psychedelic pipeline and strong 2025 rally have Jones Trading penciling in gains that could more than quadruple the stock from here.

Barchart

MarketBeat’s Top 5 Rated Small-Cap Stocks

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

MarketBeat

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health disorders.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Insider Report: Panic Never Pays

It was a pretty quiet week until Friday. Trade tensions with China are soaring again, and it sent stocks tumbling into the close. Could we really see 100% tariffs on China? I think it's an exaggeration, and the best dip buying opportunity in months. Be ready. The Dow Jones Industrial…

Benzinga

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

With Phase 3 results for its lead psychedelic therapy expected next year, is now the right time to take a bold bet on MNMD stock?

Barchart

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

Two psychedelic-focused stocks stand to benefit after the FDA designated psychedelics as a top review priority.

Barchart

1 Small-Cap Biotech That Analysts Expect to Triple

As psychedelic treatments gain traction, analysts predict triple-digit upside for this small-cap biotech stock.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Buy the Dip in This Biotech After Negative FDA News, Says Analyst

MindMed is a high-flying pre-revenue company that has more than doubled investor returns in the last 12 months.

Barchart

3 Growth Stocks Under $10 With Breakout Potential

Discover three under-the-radar biotech and medtech stocks that analysts believe could soar in 2024, each with unique growth drivers and significant upside potential.

Barchart

Up 163% YTD, Is It Too Late to Buy MindMed Stock?

Mind Medicine is a pre-revenue biopharma company that has more than doubled investor returns in 2024. Is MNMD stock a good buy today?

Barchart

MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials

Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.

Benzinga

Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Benzinga

Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session

Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.

Benzinga

Why Crypto-Related Stocks Are Trading Lower: Here Are 34 Stocks Moving Premarket

Gainers

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.

Benzinga

This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket

Gainers

Benzinga

Numinus Wellness, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Numinus Wellness (OTC:NUMIF) shares closed up 13.88% at $0.20

Benzinga

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today

GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78

Benzinga

ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36

Benzinga

Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International

Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department.

Benzinga

Psychedelic Stock Gainers And Losers From May 20, 2022

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 8.33% at $0.77

Benzinga

Earnings Preview For Mind Medicine

Mind Medicine (NASDAQ:MNMD) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Mind Medicine will report an earnings per share (EPS) of $-0.05.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022

Upgrades

Benzinga

Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87

1 2

People

John Miller

77 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.